Advances in pharmacotherapy for the treatment of peritoneal metastases from colorectal cancer

Expert Opinion on Pharmacotherapy, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 27, 2024

Introduction Patients with peritoneal metastasis (PM) from colorectal cancer (CRC) typically have a poor prognosis historically few treatment options. Cytoreductive surgery (CRS) is the mainstay of to remove macrometastases into peritoneum, but residual micrometastases are often left behind. Systemic chemotherapy remains cornerstone for micrometastases, intraperitoneal therapy offers advantages including higher local dose concentration fewer systemic side effects treatment.

Language: Английский

Bioengineered miR-7-5p modulates non-small cell lung cancer cell metabolism to improve therapy

Molecular Pharmacology, Journal Year: 2024, Volume and Issue: 107(1), P. 100006 - 100006

Published: Nov. 29, 2024

Reintroduction of tumor-suppressive microRNA-7-5p (miR-7) that is depleted in non-small cell lung cancer (NSCLC) represents a new therapeutic approach, whereas previous studies mainly used miR-7 mimics chemoengineered vitro. Here we aim to establish the pharmacological actions and potential novel bioengineered RNA bearing payload (BioRNA/miR-7) molecule produced vivo. First, through confocal imaging immunoblot studies, revealed BioRNA/miR-7 altered NSCLC mitochondrial morphology accompanied by downregulation known target genes, epidermal growth factor receptor (EGFR), solute carrier family 25A37 (SLC25A37), import inner membrane translocase subunit (TIM50). Second, luciferase reporter validated acylglycerol kinase (AGK) as direct for miR-7. Third, real-time live-cell analyses, modulate respiration glycolytic capacity. Fourth, endpoint viability demonstrated combination with pemetrexed (PEM) elicited strong synergistic effect inhibit growth, associated an increased intracellular PEM accumulation, quantified liquid chromatography tandem mass spectrometry method. Finally, vivo therapy study using patient-derived xenograft mouse model, efficacy tolerability monotherapy control tumor progression. Our collective works role metabolism disposition support our novel, BioRNA/miR-7-5p molecular research. findings further illustrate plus treatment combat SIGNIFICANCE STATEMENT: MiR-7 microRNA (NSCLC), vitro were shown cell-derived mice. Here, molecule, namely BioRNA/miR-7, was effectively gene expression metabolism. Furthermore, remarkably improve antitumor activity mice, supporting therapy.

Language: Английский

Corosolic acid derivative-based lipid nanoparticles for efficient RNA delivery

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 378, P. 1 - 17

Published: Dec. 7, 2024

Language: Английский